Bihter Atil Selected Research

KP 1339

10/2013	The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo.
6/2010	Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bihter Atil Research Topics

Disease

3	Neoplasms (Cancer) 01/2016 - 06/2010
2	Rhabdomyosarcoma 01/2016 - 07/2013
1	Neuroblastoma 01/2016
1	Melanoma (Melanoma, Malignant) 08/2015
1	Hepatocellular Carcinoma (Hepatoma) 10/2013

Drug/Important Bio-Agent (IBA)

3	Simvastatin (Zocor)FDA LinkGeneric 01/2016 - 07/2013
2	ATP-Binding Cassette Transporters (ABC Transporters)IBA 01/2016 - 07/2013
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2016 - 07/2013
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2016 - 08/2015
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2016 - 07/2013
2	KP 1339IBA 10/2013 - 06/2010
1	Adenosine Triphosphate (ATP)IBA 01/2016
1	Coenzyme A (CoA)IBA 01/2016
1	DolicholsIBA 01/2016
1	Caspase 3 (Caspase-3)IBA 08/2015
1	tocilizumab (atlizumab)FDA Link 08/2015
1	InterleukinsIBA 08/2015
1	Interleukin-6 (Interleukin 6)IBA 08/2015
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 08/2015
1	Phosphotransferases (Kinase)IBA 10/2013
1	Sorafenib (BAY 43-9006)FDA Link 10/2013
1	Drug CombinationsIBA 10/2013
1	Type II DNA Topoisomerases (Topoisomerase II)IBA 07/2013
1	indazolium trans- (tetrachlorobis(1H- indazole)ruthenate (III))IBA 06/2010
1	Proteins (Proteins, Gene)FDA Link 06/2010
1	RutheniumIBA 06/2010

Therapy/Procedure

2	Therapeutics 01/2016 - 10/2013